| Balance sheet (USD) | FY 2025 ended Dec 31, 2025 | FY 2024 ended Dec 31, 2024 | FY 2023 ended Dec 31, 2023 | FY 2022 ended Dec 31, 2022 | FY 2021 ended Dec 31, 2021 | FY 2020 ended Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 7.27B | 3.27B | 2.82B | 2.07B | 3.82B | 3.66B |
| Short-term investments | 154.80M | 109.10M | 144.80M | 90.10M | 24.20M | |
| Receivables | 17.76B | 11.01B | 9.09B | 6.90B | 6.67B | 5.88B |
| Inventory | 13.74B | 7.59B | 5.77B | 4.31B | 3.89B | 3.98B |
| Total current assets | 55.63B | 32.74B | 25.73B | 18.03B | 18.45B | 17.46B |
| Property, plant and equipment | 24.68B | 17.10B | 12.91B | 10.14B | 8.99B | 8.68B |
| Goodwill and intangibles | 12.42B | 11.94B | 11.85B | 11.28B | 11.58B | 11.22B |
| Total assets | 112.48B | 78.72B | 64.01B | 49.49B | 48.81B | 46.63B |
| Accounts payable | 5.38B | 3.23B | 2.60B | 1.93B | 1.67B | 1.61B |
| Total current liabilities | 35.23B | 28.38B | 27.29B | 17.14B | 15.05B | 12.48B |
| Long-term debt | 40.87B | 28.53B | 18.32B | 14.74B | 15.35B | 16.59B |
| Total liabilities | 85.94B | 64.44B | 53.23B | 38.84B | 39.83B | 40.99B |
| Retained earnings | 24.47B | 13.54B | 10.31B | 10.04B | 8.96B | 7.83B |
| Shareholders' equity | 26.54B | 14.27B | 10.77B | 10.65B | 8.98B | 5.64B |
| Total debt | 42.50B | 37.98B | 31.41B | 17.74B | 16.88B | 16.60B |
| Net debt | 35.23B | 34.71B | 28.60B | 15.67B | 13.07B | 12.94B |
From Eli Lilly's 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.